Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology.
The incidence of invasive fungal disease (IFD) is rising, but its treatment in paediatric haematology and oncology patients is not yet standardised. This review aimed to critically appraise and analyse the clinical practice guidelines (CPGs) that are available for paediatric IFD.



Electronic searches of MEDLINE, MEDLINE in-Process & Other non-Indexed Citations, the Guidelines International Network (GIN), guideline.gov and Google were performed and combined fungal disease (Fung* OR antifung*OR Candida* OR Aspergill*) with prophylaxis or treatment (prophyl* OR therap* OR treatment). All guidelines were assessed using the AGREE II tool and recommendations relating to prophylaxis, empirical treatment and specific therapy were extracted.



Nineteen guidelines met the inclusion criteria. The AGREE II scores for the rigour of development domain ranged from 11 to 92 % with a median of 53 % (interquartile range 32-69 %). Fluconazole was recommended as antifungal prophylaxis in all nine of the included guidelines which recommended a specific drug. Liposomal amphotericin B was recommended in all five guidelines giving empirical therapy recommendations. Specific therapy recommendations were given for oral or genital candidiasis, invasive candida infection, invasive aspergillosis and other mould infections.



In many areas, recommendations were clear about appropriate practice but further clarity was required, particularly relating to the decision to discontinue empirical antifungal treatment, the relative benefits of empiric and pre-emptive strategies and risk stratification. Future CPGs could consider working to published guideline production methodologies and sharing summaries of evidence appraisal to reduce duplication of effort, improving the quality and efficiency of CPGs in this area.
Centre for Reviews and Dissemination, University of York, York, YO10 5DD, UK. jem539@york.ac.uk.|Department of Paediatric Haematology and Oncology, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds, LS1 3EX, UK. jem539@york.ac.uk.
Jessica E
JE
Morgan
Department of Paediatric Haematology and Oncology, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds, LS1 3EX, UK.
Hadeel
H
Hassan
Department of Paediatric Haematology and Oncology, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds, LS1 3EX, UK.
Julia V
JV
Cockle
Department of Paediatric Haematology and Oncology, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds, LS1 3EX, UK.
Christopher
C
Lethaby
Department of Paediatric Haematology and Oncology, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds, LS1 3EX, UK.
Beki
B
James
Centre for Reviews and Dissemination, University of York, York, YO10 5DD, UK.|Department of Paediatric Haematology and Oncology, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds, LS1 3EX, UK.
Robert S
RS
Phillips
D000935:Antifungal Agents / Q000627:therapeutic use*; D002648:Child; D006405:Hematology / Q000379:methods / Q000592:standards*; D006801:Humans; D008495:Medical Oncology / Q000379:methods / Q000592:standards*; D009181:Mycoses / Q000517:prevention & control*; D009369:Neoplasms / Q000382:microbiology* / Q000628:therapy*; D010372:Pediatrics / Q000379:methods / Q000592:standards*; D017410:Practice Guidelines as Topic / Q000592:standards*
D000935:Antifungal Agents
Critical review; Fungal infection; Guideline; Paediatric